Drug intelligence / Profile preview

AS-8112

Development stage: Unknown
Lead developer: Sumitomo Pharma
Modality: Small Molecules
Administration: Unknown (preclinical/experimental Stage)[5]

Overview

AS-8112 is a synthetic small molecule that acts as a selective antagonist at dopamine receptor subtypes D2 and D3 and the serotonin receptor 5-HT3. It has demonstrated potent antiemetic effects in animal studies by centrally inhibiting emesis induced by agents such as cisplatin and dopaminergic agonists. The drug was initially developed for potential use in treating nausea and vomiting but did not progress beyond preclinical development[1][2][3][5][7].

Other names: 5-bromo-N-[(6R)-1-ethyl-4-methyl-1,4-diazepan-6-yl]-2-methoxy-4-(methylamino)benzamideDB09207DB-09207DB 09207NS00073401NS-00073401NS 00073401

Targets

DRD3 (Dopamine receptor D3)HTR3A (5-hydroxytryptamine receptor 3A)DRD2 (Dopamine D2 Receptor)

Beyond the preview

Go deeper on AS-8112.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AS-8112.

Explore the full profile